Immuneering Corporation Insider Trading
IMRX
Insiders bought 360K on the open market and sold nothing.
Get an email when IMRX's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13 | Andrew Gengos Chief Financial Officer | Bought | 25,000 | $3.58 | 90K | 11% | Form 4 |
| Jun 23 | Benjamin J. Zeskind President and CEO | Bought | 2,400 | $4.56 | 11K | <0.1% | Form 4 |
| Jun 15 | Brett Matthew Hall Chief Scientific Officer | Bought | 6,035 | $4.15 | 25K | 1.6% | Form 4 |
| Jan 16 | Harold Eugene Brakewood Chief Business Officer | Bought | 5,250 | $4.76 | 25K | 91% | Form 4 |
| Jan 15 | Thomas J. Schall Director | Bought | 21,645 | $4.67 | 101K | 41% | Form 4 |
| Jan 15 | Brett Matthew Hall Chief Scientific Officer | Bought | 2,298 | $4.57 | 11K | 0.6% | Form 4 |
| Jan 13 | Leah R Neufeld Chief People Officer | Bought | 2,626 | $4.15 | 11K | 11% | Form 4 |
| Jan 12 | Peter Feinberg Director | Bought | 20,000 | $4.35 | 87K | 1.8% | Form 4 |
| Oct 3, 2025 | Peter Feinberg Director | Bought | 7,500 | $6.67 | 50K | 0.7% | Form 4 |
| Oct 1, 2025 | Mallory Morales Chief Accounting Officer | Bought | 300 | $6.39 | 2K | 1.1% | Form 4 |
| Oct 1, 2025 | Leah R Neufeld Chief People Officer | Bought | 800 | $6.38 | 5K | 3.5% | Form 4 |
| Oct 1, 2025 | Michael Bookman Chief Legal Officer, Secretary | Bought | 1,020 | $6.83 | 7K | 26% | Form 4 |
| Sep 30, 2025 | Peter Feinberg Director | Bought | 7,500 | $7.03 | 53K | 0.7% | Form 4 |
| Sep 29, 2025 | Peter Feinberg Director | Bought | 5,000 | $7.18 | 36K | 0.4% | Form 4 |
| Jul 2, 2025 | Diana Hausman Director | Bought 2 parts | 5,500 | $3.61 average | 20K | New | Form 4 |
| Jul 2, 2025 | Leah R Neufeld Chief People Officer | Bought | 700 | $3.57 | 2K | 7.0% | Form 4 |
| Jul 1, 2025 – Jul 2, 2025 | Benjamin J. Zeskind President and CEO | Bought 2 parts | 10,000 | $3.49 average | 35K | 0.3% | Form 4 |
| Jun 27, 2025 | Thomas J. Schall Director | Bought | 9,500 | $3.66 | 35K | 22% | Form 4 |
| Jun 20, 2025 – Jun 23, 2025 | Brett Matthew Hall Chief Scientific Officer | Bought 2 parts | 13,422 | $2.58 average | 35K | 3.9% | Form 4 |
| Jun 20, 2025 | Harold Eugene Brakewood Chief Business Officer | Bought | 1,900 | $2.53 | 5K | 49% | Form 4 |
| Jun 18, 2025 | Peter Feinberg Director | Bought | 25,000 | $2.53 | 63K | 2.3% | Form 4 |
| Jun 18, 2025 | Benjamin J. Zeskind President and CEO | Bought | 21,000 | $2.39 | 50K | 0.7% | Form 4 |
| Jun 17, 2025 | Thomas J. Schall Director | Bought | 40,485 | $2.21 | 89K | 1396% | Form 4 |
- Nov 13Andrew GengosChief Financial Officer · bought 25,000 at $3.5890K11% of stake
- Jun 23Benjamin J. ZeskindPresident and CEO · bought 2,400 at $4.5611K<0.1% of stake
- Jun 15Brett Matthew HallChief Scientific Officer · bought 6,035 at $4.1525K1.6% of stake
- Jan 16Harold Eugene BrakewoodChief Business Officer · bought 5,250 at $4.7625K91% of stake
- Jan 15Thomas J. SchallDirector · bought 21,645 at $4.67101K41% of stake
- Jan 15Brett Matthew HallChief Scientific Officer · bought 2,298 at $4.5711K0.6% of stake
- Jan 13Leah R NeufeldChief People Officer · bought 2,626 at $4.1511K11% of stake
- Jan 12Peter FeinbergDirector · bought 20,000 at $4.3587K1.8% of stake
- Oct 3, 2025Peter FeinbergDirector · bought 7,500 at $6.6750K0.7% of stake
- Oct 1, 2025Mallory MoralesChief Accounting Officer · bought 300 at $6.392K1.1% of stake
- Oct 1, 2025Leah R NeufeldChief People Officer · bought 800 at $6.385K3.5% of stake
- Oct 1, 2025Michael BookmanChief Legal Officer, Secretary · bought 1,020 at $6.837K26% of stake
- Sep 30, 2025Peter FeinbergDirector · bought 7,500 at $7.0353K0.7% of stake
- Sep 29, 2025Peter FeinbergDirector · bought 5,000 at $7.1836K0.4% of stake
- Jul 2, 2025Diana HausmanDirector · bought 5,500 at avg $3.6120KNew position
- Jul 2, 2025Leah R NeufeldChief People Officer · bought 700 at $3.572K7.0% of stake
- Jul 1, 2025 – Jul 2, 2025Benjamin J. ZeskindPresident and CEO · bought 10,000 at avg $3.4935K0.3% of stake
- Jun 27, 2025Thomas J. SchallDirector · bought 9,500 at $3.6635K22% of stake
- Jun 20, 2025 – Jun 23, 2025Brett Matthew HallChief Scientific Officer · bought 13,422 at avg $2.5835K3.9% of stake
- Jun 20, 2025Harold Eugene BrakewoodChief Business Officer · bought 1,900 at $2.535K49% of stake
- Jun 18, 2025Peter FeinbergDirector · bought 25,000 at $2.5363K2.3% of stake
- Jun 18, 2025Benjamin J. ZeskindPresident and CEO · bought 21,000 at $2.3950K0.7% of stake
- Jun 17, 2025Thomas J. SchallDirector · bought 40,485 at $2.2189K1396% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with IMRX
Held by ETFs
IMRX is in 6 US ETFs. The largest of them, with IMRX's weight in each:
Spot a number that looks wrong? Check it in IMRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.